New data were presented at the American Society of Clinical Oncology meeting in June 2010 in Chicago regarding the role of axillary management in the treatment of early stage breast cancer. Join Dr. Harold Burstein as he leads a multidisciplinary case discussion that confronts the question of how these new data may alter your practice now or in the future. Joining Dr. Burstein, an oncologist, are Dr. Jennifer Bellon, MD, an interventional radiologist, and Dr. Mehra Golshan, a surgeon. This course is part of the The Advanced Certificate Program in Breast Cancer Management III.
Drs. Burstein, Bellon, and Golshan provide key takeaway messages from their discussion, including how these presented data may alter clinical practice now and in the future and contribute to the goal of tailored therapy.
Drs. Burstein, Bellon, and Golshan consider a number of patient and clinical variables that influence decisions regarding management strategy.
The panel discusses the role of adjuvant radiotherapy and additional diagnostics, including immunohistochemistry and imaging studies, in axillary management of early-stage breast cancer.
Dr. Jennifer Bellon, a radiation oncologist, and Dr. Mehra Golshan, a surgeon, discuss the findings of the ACOSOG Z0011 trial, which compared complete dissection to sentinel lymph node dissection in terms of survival and recurrence.
After introducing the faculty, Dr. Harold Burstein presents a case that illustrates the role of axillary management in the treatment of early-stage breast cancer in light of historical risk assessment and new data presented at the 2010 ASCO meeting.
© 2020-2025 Ivy Podcast Discovery LLC
